Life Sciences Tools and Services
Company Overview of Cato Research Ltd.
Cato Research Ltd., a contract research and development organization, provides strategic and tactical support for pharmaceutical, biotechnology, and medical device industries in North America and internationally. The company offers services ranging from the design and management of preclinical and clinical studies to the submission of regulatory documents required for marketing approval. It also provides clinical trial, regulatory, medical and pharmacovigilance, nonclinical safety, data management and biostatistics, medical writing, quality assurance, project management, and investigator registry services; and chemistry, manufacturing, and control services. Cato Research Ltd. was founded in ...
4364 South Alston Avenue
Westpark Corporate Center
Durham, NC 27713-2220
Founded in 1988
Key Executives for Cato Research Ltd.
Chief Legal Officer and Vice President of Corporate Development
Chief Operating Officer of CRSD
Compensation as of Fiscal Year 2014.
Cato Research Ltd. Key Developments
Pluristem Therapeutics, Inc. Selects Cato Research Ltd. as Contract Research Organization
Aug 13 12
Pluristem Therapeutics Inc. announced it has selected Cato Research Ltd. as its contract research organization (CRO) for the German portion of the company's phase II trial in intermittent claudication (IC) under the auspices of the Paul-Ehrlich Institute (PEI). Cato will serve as Pluristem's applicant for its IC Clinical Trial Application to the PEI and to the ethics committees of the three study sites where the trials will be conducted. The trial will evaluate the safety and efficacy of Pluristem's PLacental eXpanded (PLX-PAD) cells in treating IC, a subset of peripheral artery disease (PAD). The prevalence of IC in the United States alone is approximately 14 million patients, representing a cost of approximately $2.5 billion annually to the healthcare system. In addition to Germany, Pluristem's multinational Phase II trial in IC will also include 11 sites in the United States and 2 sites in Israel with the US Food and Drug Administration (FDA) already approving the United States portion of this study. The trial will enroll 150 patients in a randomized, double blinded, placebo controlled study evaluating two doses of either 150 or 300 million PLX cells given intramuscularly three months apart. The primary endpoint of the trial will be maximum walking distance achieved on a treadmill at 12 months.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries